| News | Events |
| Publications | Companies |
| Clinical Trials |
Monthly Archives: November 2007
-
Contine Reading & Discuss→
-
Contine Reading & Discuss→Holding in Company
0 Replies
-
Contine Reading & Discuss→Silence Therapeutics Appoints Financial Adviser and Broker and Nominated Adviser
0 Replies
-
Contine Reading & Discuss→Silence Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
0 Replies
-
Contine Reading & Discuss→Silence Therapeutics plc announces that a 2nd siRNA therapeutic based upon its unique proprietary chemistry has moved into clinical development
0 Replies
-
Contine Reading & Discuss→Holding in Company
0 Replies
-
Contine Reading & Discuss→Holding in Company
0 Replies
-
Contine Reading & Discuss→Total Voting Rights~
0 Replies
-
Contine Reading & Discuss→Silence Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
0 Replies
-
The Company’s collaboration partner Enzon Pharmaceuticals, Inc. has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule read more Contine Reading & Discuss→Santaris Pharma’s HIF-1 alpha antagonist begins second phase 1 study
0 Replies

